Skip to main content
OpenTrials
Completed

NCT Number: NCT06882551

Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients

Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Macular Edema (DME)

Age range

32 year–78 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Khyber Teaching Hospital

Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan

About this study

Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema. Those patients who had glaucoma history or IOP above 21 mm of Hg, Phakic, corneal opacity, vitreous hemorrhage, proliferative diabetic retinopathy, already received anti-VEGF injections, history of pan-retinal photocoagulation for proliferative diabetic retinopathy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with center involving diabetic macular edema on optical coherence tomography

Exclusion criteria

  • Raised intraocular pressure
  • History of glaucoma
  • Corneal opacity
  • Vitreous hemorrhage
  • Proliferative diabetic retinopathy
  • Anti-VEGF injections in last 3 months
  • History of pan-retinal photocoagulation
  • Contraindications for anti-VEGF

Treatment and study plan

Intravitreal Bevacizumab IVB

Drug

Intravitreal bevacizumab alone

intravitreal bevacizumab and suprachoroidal triamcinolone acetonide

Drug

Combination of Intravitreal bevacizumab and suprachoroidal triamcinolone acetonide

Primary outcomes

  1. Central macular thickness

    Time frame: 3 months

    Effect of both treatment on central macular thickness measure on optical coherence tomography

  2. Visual Acuity

    Time frame: 3 months

    Improvement in best corrected visual acuity

Sponsors and collaborators

Lead sponsor

Khyber Teaching Hospital

Other

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Mar 18, 2025
Registry last updated
Mar 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.